MedTrace Logo

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

NCT05620134 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 263

Last updated 2024-10-15

No results posted yet for this study

Summary

This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer.

Conditions

Interventions

DRUG

JK08

Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.

DRUG

Pembrolizumab

Immune checkpoint inhibitor

DRUG

Lenvatinib Pill

Multi-kinase inhibitor

Sponsors & Collaborators

  • Salubris Biotherapeutics Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2025-10-17
Completion
2026-02-20

Countries

  • Belgium
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05620134 on ClinicalTrials.gov